A Brisbane law firm has filed a class action against Johnson & Johnson alleging the pharmaceutical giant made false claims about the effectiveness of popular brands of cold and flu medication.

Summary

A class action lawsuit has been filed in Australia against Johnson & Johnson, accusing the company of misleading consumers by selling cold and flu medications with phenylephrine, an ineffective oral nasal congestion ingredient.

Products like Codral PE and Sudafed PE replaced pseudoephedrine with phenylephrine in 2006 after stricter regulations.

Lawyers argue consumers were “duped” into buying ineffective products at premium prices.

If successful, buyers since 2005 could be compensated. The TGA is monitoring FDA findings but has no current plans to review oral phenylephrine’s effectiveness.

  • @ForgotAboutDreEnglish
    3•27 days ago

    It’s normal for these types of agencies to make their own judgments, they shouldn’t assume the FDA knows better. Population and genetic differences shouldn’t matter and won’t be a factor.